Quick Answer
Aldeyra Therapeutics, Inc. reported Total Assets of $72.06 million for the year ending 2025.
- Aldeyra Therapeutics, Inc. showed a decrease of -31.1% in Total Assets from 2024 to 2025.
- This data is from Aldeyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $2.89 million | Q2 2014: $11.81 million | Q3 2014: $10.35 million | Q1 2015: $15.93 million | Q2 2015: $33.88 million | Q3 2015: $31.35 million | Q1 2016: $23.44 million | Q2 2016: $32.88 million | Q3 2016: $29.19 million | Q1 2017: $31.53 million | Q2 2017: $26.47 million | Q3 2017: $49.23 million | Q1 2018: $40.78 million | Q2 2018: $43.29 million | Q3 2018: $37.13 million | Q1 2019: $88.13 million | Q2 2019: $73.84 million | Q3 2019: $77.44 million | Q1 2020: $63.03 million | Q2 2020: $71.63 million | Q3 2020: $88.32 million | Q1 2021: $147.31 million | Q2 2021: $256.43 million | Q3 2021: $247.22 million | Q1 2022: $222.69 million | Q2 2022: $201.02 million | Q3 2022: $189.69 million | Q1 2023: $168.22 million | Q2 2023: $155.62 million | Q3 2023: $147.28 million | Q1 2024: $141.30 million | Q2 2024: $126.04 million | Q3 2024: $117.32 million | Q1 2025: $93.20 million | Q2 2025: $84.96 million | Q3 2025: $77.80 million.
- Over the full 13 years of available data (2013 to 2025), Aldeyra Therapeutics, Inc.'s Total Assets has grown by 1,825.1%.
- Historical annual values: Fiscal year 2025: $72.06 million | Fiscal year 2024: $104.61 million | Fiscal year 2023: $148.33 million | Fiscal year 2022: $181.29 million | Fiscal year 2021: $233.14 million | Fiscal year 2020: $83.35 million | Fiscal year 2019: $75.52 million | Fiscal year 2018: $95.09 million | Fiscal year 2017: $44.17 million | Fiscal year 2016: $25.19 million | Fiscal year 2015: $28.20 million | Fiscal year 2014: $8.79 million | Fiscal year 2013: $3.74 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: